Resverlogix Corp. reported success in a Phase IIb (SUSTAIN) trial of its small-molecule BET protein inhibitor, RVX-208, designed to increase levels of high-density lipoprotein cholesterol (HDL-C) in patients with atherosclerosis. Read More
While the FDA Safety and Innovation Act (FDASIA) includes a number of provisions to ensure the quality of drugs and protect against counterfeits, it's what it's missing that could have the biggest impact on the supply chain in a few years. Read More
Shares of TopoTarget A/S gained 10 percent Tuesday following an additional analysis of data from a Phase II trial of belinostat in 89 patients with cancer of unknown primary (CUP) origin, which raises hopes that the drug, a histone deacetylase inhibitor, could have potential in solid tumors. Read More
LONDON – Spinifex Pharmaceuticals announced positive Phase II results of EMA401 in controlling neuropathic pain following herpes zoster (shingles) infection, and the company is now weighing the commercialization strategy for the product. Read More
Gilead Sciences Inc. said it expects to have its four-drug, single-tablet regimen Stribild, formerly known as Quad, available to patients by the end of this week, following the drug's approval Monday for treatment-naïve patients with HIV-1 infection. Read More
• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., agreed to sell 4 million shares of its common stock and warrants to purchase an aggregate of 1.2 million shares of common stock in a registered direct public offering. Read More
• Bolder BioTechnology Inc., of Boulder, Colo., published a study showing that its long-acting inerleukin-11 analogue prevented kidney damage from ischemia reperfusion injury in mice. The research was carried out at Columbia University, and published online in the American Journal of Physiology. Read More
• Evolva Holding SA, of Reinach, Switzerland, reported further data for the first 32 patients enrolled in its Phase IIa study of EV-077, a reversible antagonist of isoprostanes and prostanoids, showing that, when given orally to Type II diabetes patients, the drug provided antiplatelet activity, reduced exercise-induced proteinuria and increased forearm blood flow. Read More
